(Beijing Comprehensive News) Paxlovid, a crown disease oral drug produced by Pfizer, failed to be included in medical insurance, officials of the National Medical Security Bureau said that the price problem is the reason for the breakdown of the negotiations, and it is emphasized that the Medical Insurance Bureau has taken out that it is "very large.Sincerity ", will no longer hold special negotiations on Paxlovid.
According to the official media and People's Daily, Huang Xinyu, deputy director of the Medical Service Management Department of the Medical Insurance Bureau, was interviewed by the media on Wednesday (January 18).The huge use of people, but the official also must "consider the fund's tolerance and the social affordability of society, not all resources can be invested on one medicine."
Huang Xinyu emphasized that although PaxLovid is not a "special effect medicine", from the perspective of clinical manifestations and existing evidence, it does have a good effect.
He also said that the price of each drug has different standards in different countries. Pharmaceutical companies may have their own considerations, but the negotiation of the Traditional Chinese Medicine Bureau also gives great sincerity.
Another relevant person revealed that the official would no longer hold a special negotiation with Paxlovid.
Some media had previously quoted "Zhang Ning, a person in China" that Pfizer once dropped the offer to 600 yuan (RMB, the same, about S $ 120) in the negotiations, but the Medical Insurance Bureau bargained to 200 yuanOnly finally led to the breakdown of the negotiation.
However, the Beijing News quoted anonymous insiders on Wednesday that the actual quotation was much higher than that, and the failure of negotiations was not because the reserve price issued by the Medical Insurance Bureau was too low.
The person familiar with the matter said that Pfizer basically did not reduce the price during the negotiation process, and when the negotiations were in PAXLOVID, Vice President Pfizer, who was originally responsible for negotiation, had left the scene.
People familiar with the matter believe that although who and how to talk about it are all corporate strategies, the combination of the above two performances, the willingness to express in the enterprise is "quite obvious."
The annual negotiations between the Medical Insurance Bureau and the pharmaceutical company have been described as "the soul bargain" by Chinese official media.
According to the data released by the Medical Insurance Bureau, the average price of the newly admitted drugs successfully decreased by 60.1 % of the successful negotiations, which was basically the same as last year.Among them, the Chinese domestic crown disease oral medicine Azf's fixed table was successfully selected at a price reduction by about 50 %.
President President Alber on the 9th of this month responded to the failure of the China National Medical Insurance Administration on the failure of the PAXLOVID negotiations that the offer required by China is lower than the minimum quotation of middle -income countries. "As the second largest economy in the world, I am notIt is believed that China should pay a lower price than Salvador. "
